Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | EVP & CSO | March 10, 2017 | March 15, 2017 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | Director | May 12, 2022 | May 13, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date March 10, 2017 · Filed March 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 321,905.531 |
Ending reported balance
After 2017-03-10 transaction · row 14
14 source rows · reconciled sequenceRow 1 · 2017-03-10 · Exercise / conversion · Acquired 2,740 · Balance 292,471.531 F1: Represents vesting of one-quarter of market share units granted on March 10, 2013. Row 2 · 2017-03-10 · Other · Acquired 1,343 · Balance 293,814.531 F2: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Row 3 · 2017-03-10 · Tax withholding · Disposed 2,022 · Balance 291,792.531 F3: Shares withheld for payment of taxes upon vesting of awards. Row 4 · 2017-03-10 · Exercise / conversion · Acquired 5,279 · Balance 297,071.531 F4: Represents vesting of one-quarter of market share units granted on March 10, 2014. Row 5 · 2017-03-10 · Other · Acquired 41 · Balance 297,112.531 F2: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. Row 6 · 2017-03-10 · Tax withholding · Disposed 2,759 · Balance 294,353.531 F3: Shares withheld for payment of taxes upon vesting of awards. Row 7 · 2017-03-10 · Exercise / conversion · Acquired 4,982 · Balance 299,335.531 F5: Represents vesting of one-quarter of market share units granted on March 10, 2015. Row 8 · 2017-03-10 · Other · Disposed 653 · Balance 298,682.531 F6: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Row 9 · 2017-03-10 · Tax withholding · Disposed 2,245 · Balance 296,437.531 F3: Shares withheld for payment of taxes upon vesting of awards. Row 10 · 2017-03-10 · Exercise / conversion · Acquired 5,772 · Balance 302,209.531 F7: Represents vesting of one-quarter of market share units granted on March 10, 2016. Row 11 · 2017-03-10 · Other · Disposed 831 · Balance 301,378.531 F6: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor. Row 12 · 2017-03-10 · Tax withholding · Disposed 2,562 · Balance 298,816.531 F3: Shares withheld for payment of taxes upon vesting of awards. Row 13 · 2017-03-10 · Exercise / conversion · Acquired 47,953 · Balance 346,769.531 F8: Amount represents distribution of performance shares earned under the 2014-2016 Long-Term Performance Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board. Row 14 · 2017-03-10 · Tax withholding · Disposed 24,864 · Balance 321,905.531 F3: Shares withheld for payment of taxes upon vesting of awards. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2017-03-10 | Direct | 0 |
Reported balance
After 2017-03-10 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2017-03-10 · Exercise / conversion · Disposed 2,740 · Balance 0 F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F1: Represents vesting of one-quarter of market share units granted on March 10, 2013. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2018-03-10 | Direct | 5,280 |
Reported balance
After 2017-03-10 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2017-03-10 · Exercise / conversion · Disposed 5,279 · Balance 5,280 F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F4: Represents vesting of one-quarter of market share units granted on March 10, 2014. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2019-03-10 | Direct | 9,966 |
Reported balance
After 2017-03-10 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2017-03-10 · Exercise / conversion · Disposed 4,982 · Balance 9,966 F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F5: Represents vesting of one-quarter of market share units granted on March 10, 2015. |
| Market Share UnitsSEC Table II · derivative / convertible security · Expires 2020-03-10 | Direct | 17,318 |
Reported balance
After 2017-03-10 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2017-03-10 · Exercise / conversion · Disposed 5,772 · Balance 17,318 F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%. F7: Represents vesting of one-quarter of market share units granted on March 10, 2016. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2017-03-10 | Direct | 0 |
Reported balance
After 2017-03-10 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2017-03-10 · Exercise / conversion · Disposed 47,953 · Balance 0 F10: Each performance share converts into one share of common stock upon distribution in the first quarter of 2017, subject to a Total Shareholder Return modifier. F8: Amount represents distribution of performance shares earned under the 2014-2016 Long-Term Performance Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents vesting of one-quarter of market share units granted on March 10, 2013.
F2: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor.
F3: Shares withheld for payment of taxes upon vesting of awards.
F4: Represents vesting of one-quarter of market share units granted on March 10, 2014.
F5: Represents vesting of one-quarter of market share units granted on March 10, 2015.
F6: Represents a downward adjustment to the number of shares acquired upon the vesting of market share units due to the performance factor.
F7: Represents vesting of one-quarter of market share units granted on March 10, 2016.
F8: Amount represents distribution of performance shares earned under the 2014-2016 Long-Term Performance Award based on the performance factor applied in accordance with the terms of the Award and certification of performance results by the Board.
F9: Each market share unit converts into the number of shares of common stock determined by applying a payout factor to the target number of shares vesting on a given date. The payout factor is a ratio of the average of the closing price on the measurement date plus the nine prior trading days divided by the average stock price on the grant date (also a 10-day average). The minimum payout factor that must be achieved to earn a payout is 60% and the maximum payout factor is 200%.
F10: Each performance share converts into one share of common stock upon distribution in the first quarter of 2017, subject to a Total Shareholder Return modifier.
Rubius Therapeutics, Inc.
Report date May 12, 2022 · Filed May 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.24 · Expires 2032-05-11 | Direct | 25,000 |
Reported balance
After 2022-05-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-05-12 · Grant · Acquired 25,000 · Balance 25,000 F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mural Oncology plc
Report date December 05, 2025 · Filed December 05, 2025
Section 16 reporting ended · disclosed 2025-12-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.56 · Expires 2035-06-10 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-05 · Disposition to issuer · Disposed 8,637 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. F1: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2034-05-29 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-12-05 · Disposition to issuer · Disposed 8,462 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.61 · Expires 2033-12-13 | Direct | 0 |
Reported balance
After 2025-12-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-05 · Disposition to issuer · Disposed 15,021 · Balance 0 F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Transaction Agreement (the "Agreement"), dated August 20, 2025, by and among the Issuer, XRA 5 Corp. ("Sub"), a Delaware corporation and wholly-owned subsidiary of XOMA Royalty Corporation, a Nevada corporation, pursuant to which Sub acquired all the issued and to be issued share capital of the Issuer (the "Acquisition") for a cash purchase price of $2.035 per share (the "Scheme Consideration"). The Acquisition was completed as of December 5, 2025 (the "Effective Time").
F2: Pursuant to the terms of the Agreement, at the Effective Time each option to purchase ordinary shares of Issuer that had an exercise price per share that was equal to or greater than the Scheme Consideration was cancelled and ceased to be outstanding, and no Scheme Consideration was delivered in exchange for such options.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 04, 2011 Filed Mar 8, 2011 22:32 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 3,038 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-009175 · doc4.xml · nonDerivative · entry 1 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,748.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares acquired upon vesting of restricted stock units. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 03, 2011 Filed Mar 5, 2011 01:58 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionRestricted Stock Units · Derivative | 3,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008909 · doc4.xml · derivative · entry 7 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,506 Underlying: Common Stock, $0.10 par value · 3,753 shares Expires 2013-03-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each restricted stock unit converts into one share of common stock upon vesting. F10 · derivative.exercise_date: Twenty-five percent of the restricted stock units will vest on each of the first, second, third and fourth anniversaries of the grant date and be converted into shares of common stock. F10 · derivative.expiration_date: Twenty-five percent of the restricted stock units will vest on each of the first, second, third and fourth anniversaries of the grant date and be converted into shares of common stock. Read SEC document |
| March 03, 2011 Filed Mar 5, 2011 01:58 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,365 | $26.14 | $35,681.10 |
DisclosureSEC source: 0001225208-11-008909 · doc4.xml · nonDerivative · entry 5 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,710.82 F6 · shares: Shares withheld for payment of taxes upon vesting of restricted stock units. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 03, 2011 Filed Mar 5, 2011 01:58 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 3,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008909 · doc4.xml · nonDerivative · entry 4 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,075.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: Shares acquired upon vesting of resticted share units. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 02, 2011 Filed Mar 5, 2011 01:58 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionMarket Share Units · Derivative | 4,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008909 · doc4.xml · derivative · entry 6 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,202 Underlying: Common Stock, $0.10 par value · 4,130 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock based on the average of the closing share price of the company's common stock on the vesting date and the nine trading days immediately preceding the vesting date. F8 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date and will be converted into shares of common stock based on a performance factor. F8 · derivative.expiration_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date and will be converted into shares of common stock based on a performance factor. Read SEC document |
| March 02, 2011 Filed Mar 5, 2011 01:58 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,557 | $25.39 | $39,532.23 |
DisclosureSEC source: 0001225208-11-008909 · doc4.xml · nonDerivative · entry 3 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,322.82 F4 · shares: Shares withheld for payment of taxes upon vesting of market share units. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 02, 2011 Filed Mar 5, 2011 01:58 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherCommon Stock, $0.10 par value | 151 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008909 · doc4.xml · nonDerivative · entry 2 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,879.82 F3 · shares: Adjustment reflects additional shares acquired upon the vesting of market share units due to the performance factor. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 02, 2011 Filed Mar 5, 2011 01:58 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 4,130 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008909 · doc4.xml · nonDerivative · entry 1 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,728.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares acquired upon vesting of market share units. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:46 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 17,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008694 · doc4.xml · derivative · entry 10 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $0.10 par value · 17,965 shares Expires 2011-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. F1 · shares: Consists of performance shares earned under the 2008-2010 Regular Long-Term Performance Award and the 2008-2010 Special Long-Term Performance Award. F9 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. F9 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:46 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionPerformance Shares · Derivative | 7,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008694 · doc4.xml · derivative · entry 9 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,816.55 Underlying: Common Stock, $0.10 par value · 7,739 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. F1 · shares: Consists of performance shares earned under the 2008-2010 Regular Long-Term Performance Award and the 2008-2010 Special Long-Term Performance Award. F9 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. F9 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:46 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | OtherPerformance Shares · Derivative | 504.55 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008694 · doc4.xml · derivative · entry 8 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,555.55 Underlying: Common Stock, $0.10 par value · 504.55 shares Expires not disclosed F12 · derivative.exercise_price: Shares represent dividend equivalents earned under the 2010-2012 regular performance share unit award and will convert into one share of common stock upon payout in the first quarter of 2013. F12 · shares: Shares represent dividend equivalents earned under the 2010-2012 regular performance share unit award and will convert into one share of common stock upon payout in the first quarter of 2013. F12 · derivative.exercise_date: Shares represent dividend equivalents earned under the 2010-2012 regular performance share unit award and will convert into one share of common stock upon payout in the first quarter of 2013. F12 · derivative.expiration_date: Shares represent dividend equivalents earned under the 2010-2012 regular performance share unit award and will convert into one share of common stock upon payout in the first quarter of 2013. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:46 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 5,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008694 · doc4.xml · derivative · entry 7 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,051 Underlying: Common Stock, $0.10 par value · 5,438 shares Expires not disclosed F10 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. F11 · shares: Consists of performance shares earned under the 2009-2011 Long-Term Performance Award. F10 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. F10 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2012. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:46 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 7,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008694 · doc4.xml · derivative · entry 6 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,613 Underlying: Common Stock, $0.10 par value · 7,739 shares Expires not disclosed F9 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. F1 · shares: Consists of performance shares earned under the 2008-2010 Regular Long-Term Performance Award and the 2008-2010 Special Long-Term Performance Award. F9 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. F9 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2011. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:46 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantPerformance Shares · Derivative | 9,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008694 · doc4.xml · derivative · entry 5 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,874 Underlying: Common Stock, $0.10 par value · 9,874 shares Expires not disclosed F7 · derivative.exercise_price: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F8 · shares: Consists of performance shares earned under the 2010-2012 Long-Term Performance Award. F7 · derivative.exercise_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. F7 · derivative.expiration_date: Each performance share converts into one share of common stock upon distribution in the first quarter of 2013. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:46 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | GrantMarket Share Units · Derivative | 14,811 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008694 · doc4.xml · derivative · entry 4 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,332 Underlying: Common Stock, $0.10 par value · 14,811 shares Expires not disclosed F5 · derivative.exercise_price: Each market share unit converts into the number of shares of common stock based on the average of the closing share price of the company's common stock on the vesting date and the nine trading days immediately preceding the vesting date. F6 · derivative.exercise_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date and will be converted into shares of common stock based on a performance factor. F6 · derivative.expiration_date: Twenty-five percent of the market share unit award will vest on each of the first, second, third and fourth anniversaries of the grant date and will be converted into shares of common stock based on a performance factor. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:46 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 5,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008694 · doc4.xml · nonDerivative · entry 3 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,598.82 F4 · shares: Shares withheld for payment of taxes upon payout of the 2008-2010 special long-term performance award. F2 · balance_after: Includes unvested restricted stock awards and dividend reinvestment shares. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:46 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 4,145 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008694 · doc4.xml · nonDerivative · entry 2 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,798.82 F3 · shares: Shares withheld for payment of taxes upon payout of the 2008-2010 regular long-term performance award. F2 · balance_after: Includes unvested restricted stock awards and dividend reinvestment shares. Read SEC document |
| March 01, 2011 Filed Mar 4, 2011 02:46 UTC | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Exercise / conversionCommon Stock, $0.10 par value | 25,704 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-008694 · doc4.xml · nonDerivative · entry 1 Cuss Francis M · CIK 0001490216 · SVP Dscvry & Exp Clinl Resrch 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,943.82 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Consists of performance shares earned under the 2008-2010 Regular Long-Term Performance Award and the 2008-2010 Special Long-Term Performance Award. F2 · balance_after: Includes unvested restricted stock awards and dividend reinvestment shares. Read SEC document |
| March 01, 2011 Filed Mar 16, 2011 20:31 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 5,200 | $25.58 | $133,016.00 |
DisclosureSEC source: 0001225208-11-009852 · doc4a.xml · nonDerivative · entry 2 Cuss Francis M · CIK 0001490216 · SVP Research, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,598.82 F3 · shares: This Form 4 is amended to report the correct price for the shares withheld for payment of taxes upon payout of the 2008-2010 special long-term performance award. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 01, 2011 Filed Mar 16, 2011 20:31 UTC Amendment | BRISTOL MYERS SQUIBB CO BMY · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 4,145 | $25.58 | $106,029.10 |
DisclosureSEC source: 0001225208-11-009852 · doc4a.xml · nonDerivative · entry 1 Cuss Francis M · CIK 0001490216 · SVP Research, R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,798.82 F1 · shares: This Form 4 is amended to report the correct price for the shares withheld for payment of taxes upon payout of the 2008-2010 regular long-term performance award. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.